These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA; JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288 [TBL] [Abstract][Full Text] [Related]
6. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Cai S; Bressler NM Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept. Chen YY; Chang PY; Wang JK Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640 [TBL] [Abstract][Full Text] [Related]
8. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema. Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058 [TBL] [Abstract][Full Text] [Related]
9. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955 [TBL] [Abstract][Full Text] [Related]
10. One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab. Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R Eur J Ophthalmol; 2021 May; 31(3):1171-1176. PubMed ID: 32452251 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794 [TBL] [Abstract][Full Text] [Related]
12. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab. Wood EH; Karth PA; Moshfeghi DM; Leng T Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice. Plaza-Ramos P; Borque E; García-Layana A PLoS One; 2019; 14(10):e0223793. PubMed ID: 31644594 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes. Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179 [TBL] [Abstract][Full Text] [Related]
15. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment. Ozkaya A; Demir G; Kirmaci A Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913 [TBL] [Abstract][Full Text] [Related]
16. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment. Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426 [No Abstract] [Full Text] [Related]
17. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema. Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552 [TBL] [Abstract][Full Text] [Related]
18. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. Krick TW; Bressler NM Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal aflibercept for diabetic macular edema. Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934 [TBL] [Abstract][Full Text] [Related]
20. Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema. Konidaris VE; Tsaousis KT; Al-Hubeshy Z; Pieri K; Deane J; Empeslidis T Eye (Lond); 2017 Nov; 31(11):1629-1630. PubMed ID: 28622326 [No Abstract] [Full Text] [Related] [Next] [New Search]